Zevra Therapeutics (ZVRA) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$199.5 million.
- Zevra Therapeutics' Enterprise Value fell 12322.44% to -$199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.5 million, marking a year-over-year decrease of 12322.44%. This contributed to the annual value of -$69.5 million for FY2024, which is 259.68% down from last year.
- As of Q3 2025, Zevra Therapeutics' Enterprise Value stood at -$199.5 million, which was down 12322.44% from -$202.6 million recorded in Q2 2025.
- Over the past 5 years, Zevra Therapeutics' Enterprise Value peaked at -$49.3 million during Q2 2024, and registered a low of -$202.6 million during Q2 2025.
- Moreover, its 5-year median value for Enterprise Value was -$82.4 million (2022), whereas its average is -$96.3 million.
- Per our database at Business Quant, Zevra Therapeutics' Enterprise Value tumbled by 312228.35% in 2021 and then skyrocketed by 4331.12% in 2024.
- Over the past 5 years, Zevra Therapeutics' Enterprise Value (Quarter) stood at -$112.3 million in 2021, then rose by 26.69% to -$82.4 million in 2022, then grew by 17.76% to -$67.7 million in 2023, then decreased by 2.6% to -$69.5 million in 2024, then crashed by 187.08% to -$199.5 million in 2025.
- Its Enterprise Value stands at -$199.5 million for Q3 2025, versus -$202.6 million for Q2 2025 and -$62.6 million for Q1 2025.